Home / Investor relations

Investor relations

Seizing Opportunities in Pharmaceutical and Chemical Manufacturing

A message from our CEO

“At Kingchem, we are at an exciting juncture. Our proven success in solving complex challenges for our clients is fueling aggressive growth plans. We invite you to partner with us as we continue to advance our industry leadership in pharmaceutical and fine chemical manufacturing.”

— Stephen Wang, Chairman of the Board, CEO, and Founding Team Member

Why Invest in Kingchem?

  • Vertically integrated model: Our unique end-to-end approach spans research, development, and manufacturing. This streamlines processes, enhances quality control standards, and accelerates time-to-market.
  • Global footprint: Our strategically located facilities in the US (St. Francis, WI) and China (Fuxin, Liaoning, and Dalian) provide a competitive advantage, offering diverse capabilities and access to key markets.
  • Strong track record: We have a proven history of delivering innovative and cost-effective solutions to the pharmaceutical, electronic, fine chemical, and specialty chemical industries.
  • Experienced leadership: Our seasoned management team possesses extensive experience and a deep understanding of the industry landscape.
  • Growth potential: We are committed to continuous expansion and investment in cutting-edge technologies to meet the growing global demand for our services.

Strategic focus areas

Kingchem is focused on expanding our capabilities and market presence in key areas:

  • cGMP manufacturing: Our FDA-registered facility in Wisconsin offers full cGMP production for pharmaceutical intermediates and APIs, adhering to the highest quality standards.
  • RSMs and specialty chemicals: Our Fuxin, China facility is a leading manufacturer of RSMs, intermediates, building blocks, and specialty chemicals, offering a wide range of chemical capabilities, including fluorination.
  • R&D excellence: Our Dalian, China R&D center is expanding, adding more scientists and engineers to focus on synthesizing advanced intermediates and developing commercial processes. The center is equipped with state-of-the-art analytical instrumentation for comprehensive research and testing.

Financial highlights

Recent IPO: Kingchem Life Science began trading on the Shenzhen Stock Exchange on August 3, 2023, providing investors with a direct opportunity to participate in our growth.

Explore investment opportunities

We invite you to explore the exciting investment opportunities at Kingchem. Join us as we continue to innovate, expand, and drive the future of pharmaceutical and chemical manufacturing.